Results 31 to 40 of about 1,026 (172)

Clinical and Economic Value of Bulevirtide in the Treatment of Chronic Hepatitis D

Gastroenterología Y Hepatología
Bulevirtide (Hepcludex®) is the first drug approved for the treatment of chronic hepatitis D (CHD), unlike the current off-label treatment (PEG-IFN-α), limited in clinical practice and associated with post-treatment relapses. In a hypothetical cohort of CHD patients in Spain, the study aim was to compare the efficiency of bulevirtide with PEG-IFN-α in ...
Maria Buti, Jose Luis Calleja-Panero, Raquel Domínguez-Hernández   +2 more
exaly   +4 more sources

HERACLIS_BLV_D: Adherence to Real-Life Therapy With Bulevirtide in Chronic Hepatitis D. [PDF]

J Viral Hepat
ABSTRACT Daily subcutaneous bulevirtide (BLV) 2 mg has been approved as first‐line treatment for chronic hepatitis D (CHD), but long‐term real‐world adherence data are limited. We assessed adherence rates during BLV therapy and their impact on treatment response. HERACLIS_BLV_D study (NCT05928000) included adult CHD patients initiating BLV 2 mg/day and
Lakiotaki D, Papatheodoridi M, Sevastianos V, Zachou K, Christodoulou D, Koskinas J, Deutsch M, Alexopoulou A, Elefsiniotis I, Triantos C, Gigi E, Androutsakos T, Karagiannakis DS, Mani I, Dimitroulopoulos D, Mela M, Sinakos E, Michopoulos S, Mimidis K, Papadopoulos N, Kontos A, Veretanos C, Lymperopoulos D, Giannoulis G, Papadimitropoulos V, Avramopoulou E, Papatheodoridi A, Pantzios S, Vasilieva L, Kranidioti H, Koullias E, Soukovelos A, Fytili P, Vlachogiannakos J, Cholongitas E, Manolakopoulos S, Goulis I, Dalekos G, Papatheodoridis G.   +38 more
europepmc   +2 more sources

Structure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCP [PDF]

Nature Communications
Cellular entry of the hepatitis B and D viruses (HBV/HDV) requires binding of the viral surface polypeptide preS1 to the hepatobiliary transporter Na+-taurocholate co-transporting polypeptide (NTCP).
Hongtao Liu, Dariusz Zakrzewicz, Kamil Nosol, Rossitza N. Irobalieva, Somnath Mukherjee, Rose Bang-Sørensen, Nora Goldmann, Sebastian Kunz, Lorenzo Rossi, Anthony A. Kossiakoff, Stephan Urban, Dieter Glebe, Joachim Geyer, Kaspar P. Locher   +13 more
doaj   +2 more sources

Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection

Pathogens, 2022
Background: The hepatitis B and D virus (HBV/HDV) hepatocyte entry inhibitor bulevirtide (BLV) has been available in Europe since July 2020, after the registrational trial MYR202. Real-life data on the efficacy and safety of BLV are sparse.
Toni Herta, Magdalena Hahn, Melanie Maier, Janett Fischer, Johannes Niemeyer, Mario Hönemann, Albrecht Böhlig, Florian Gerhardt, Aaron Schindler, Jonas Schumacher, Thomas Berg, Johannes Wiegand, Florian van Bömmel   +12 more
doaj   +1 more source

A Review of HDV Infection

Viruses, 2022
Hepatitis D is the most severe viral hepatitis. Hepatitis D virus (HDV) has a very small RNA genome with unique biological properties. It requires for infection the presence of hepatitis B virus (HBV) and is transmitted parenterally, mainly by ...
Gian Paolo Caviglia, Alessia Ciancio, Mario Rizzetto   +2 more
doaj   +1 more source

Reflex Testing for Hepatitis D Infection: A Unique Opportunity to Reduce Hepatitis D-Related Chronic Liver Disease Deaths in Australia. [PDF]

Med J Aust
ABSTRACT Chronic hepatitis D virus (HDV) infection always occurs as a coinfection with hepatitis B virus (HBV) and is the most severe form of viral hepatitis, associated with a high risk of cirrhosis, liver cancer and death. Effective treatment is now available for HDV–HBV coinfection and HDV screening is recommended for all people living with HBV, yet
Howell J, Andersson L, Levy MT, O'Beirne J, Adams L, Irvine K, Majumdar A, Ahlenstiel G, Jackson K, Hajkowicz K, Doyle J, Davies J, Cherian S, Dimech W, Thompson AJ.   +14 more
europepmc   +2 more sources

DataSheet1_Evaluation of the drug-drug interaction potential of the novel hepatitis B and D virus entry inhibitor bulevirtide at OATP1B in healthy volunteers.PDF

, 2023
Introduction: Bulevirtide is a first-in-class antiviral drug to treat chronic hepatitis B/D. We investigated the drug-drug interaction potential and pharmacokinetics of high-dose subcutaneous bulevirtide (5 mg twice daily) with organic anion transporting
Vanessa Zhu (15190573), Ute Hofmann (204608), Mathias Haag (3632419), Johanna Weiss (294205), Antje Blank (624556), Gerd Mikus (2572828), David Czock (5783999), Stephan Urban (345032), Walter E. Haefeli (784783), Jürgen Burhenne (338199), Matthias Schwab (181355)   +10 more
core   +1 more source

Prevalence of HDV infection in people living with HIV: Data from a multicenter Italian cohort

Frontiers in Medicine, 2023
ObjectivesThe development of novel antiviral agents active against Hepatitis Delta Virus (HDV) might change the natural history of chronic infection, reducing the risk for end-stage liver disease.
Laura Ambra Nicolini, Barbara Menzaghi, Elena Ricci, Emanuele Pontali, Giovanni Cenderello, Giancarlo Orofino, Antonio Cascio, Giovanni Francesco Pellicanò, Laura Valsecchi, Chiara Molteni, Francesca Vichi, Paolo Bonfanti, Paolo Bonfanti, Antonio Di Biagio, Antonio Di Biagio   +14 more
doaj   +1 more source

Intact plasma quantification of the large therapeutic lipopeptide bulevirtide [PDF]

Analytical and Bioanalytical Chemistry, 2021
AbstractBulevirtide is a first-in-class entry inhibitor of the hepatitis B and hepatitis delta virus blocking the sodium/bile acid co-transporter NTCP, and was recently approved for the treatment of hepatitis D as a priority medicine (prime) in an accelerated assessment by the European Medicines Agency.
Sauter, Max, Blank, Antje, Stoll, Felicitas, Lutz, Natalie, Haefeli, Walter E., Burhenne, Jürgen   +5 more
openaire   +2 more sources

NOVEL ENTRY INHIBITORS FOR VIRAL HEPATITIS D TREATMENT: BULEVIRTIDE [PDF]

, 2023
Chronic hepatitis D virus infection is the most severe form of viral hepatitis. Hepatitis delta virus (HDV) is a faulty RNA virus that needs hepatitis B virus surface antigen (HBsAg) for the completion of its life cycle. Hepatitis B virus (HBV) receptor,
S., MISRA, A. K., SHUKLA
core   +1 more source